Trusted Resources: Education
Scientific literature and patient education texts
Cell-Penetrating Peptide-Conjugated Morpholino Rescues SMA in a Symptomatic Preclinical Model
source: Molecular therapy : the journal of the American Society of Gene Therapy
authors: Bersani M,Rizzuti M,Pagliari E,Garbellini M,Saccomanno D,Moulton HM,Bresolin N,Comi GP,Corti S,Nizzardo Msummary/abstract:
Spinal muscular atrophy (SMA) is a motor neuron disease and the leading genetic cause of infant mortality. Recently approved SMA therapies have transformed a deadly disease into a survivable one, but these compounds show a wide spectrum of clinical response and effective rescue only in the early stages of the disease. Therefore, safe, symptomatic-suitable, non-invasive treatments with high clinical impact across different phenotypes are urgently needed. We conjugated antisense oligonucleotides with Morpholino (MO) chemistry, which increase SMN protein levels, to cell-penetrating peptides (CPPs) for better cellular distribution. Systemically administered MOs linked to r6 and (RXRRBR)XB peptides crossed the blood-brain barrier and increased SMN protein levels remarkably, causing striking improvement of survival, neuromuscular function, and neuropathology, even in symptomatic SMA animals. Our study demonstrates that MO-CPP conjugates can significantly expand the therapeutic window through minimally invasive systemic administration, opening the path for clinical applications of this strategy.organization: Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), University of Milan, Milan, Italy.
New Treatment Can Help Fresno Infant With Rare Genetic DisorderA Fresno family is holding onto hope aft...
What It Is Like to Have a Rare Disease. How Clinical Trials Changed My Life?When I was about 1, I started walking wi...
The SMA France National Registry: Already Encouraging ResultsSpinal muscular atrophy is a debilitatin...
Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Display Altered Proteomes at Early Stages of Differentiat...Spinal muscular atrophy (SMA) is an auto...
An Interview With Muscular Dystrophy Association President Donald S. WoodLarry Luxner, senior correspondent for R...
Missense Mutation in Gene Caused Psychomotor Developmental Delay and Muscle Weakness: A Case ReportThe gene encodes a part of the dynamic p...
Why Some Drugs Cost $2.1 Million per Dose and how one Company Plans to Change ThisWith a cost of $2.1 million for a one-do...